A Multicenter, Double-Blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA-101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyelonephritis

Trial Profile

A Multicenter, Double-Blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA-101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyelonephritis

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs Ceftolozane (Primary) ; Ceftazidime
  • Indications Bacterial infections; Pyelonephritis; Urinary tract infections
  • Focus Therapeutic Use
  • Sponsors Calixa Therapeutics; Cubist Pharmaceuticals
  • Most Recent Events

    • 21 Apr 2012 Additional trial locations (Czech Republic, Belgium) identified as reported by EudraCT.
    • 12 Sep 2010 Results presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
    • 30 Jun 2010 All study objectives have been met, according to a Cubist Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top